ArticleFrontiers in medicine2026
Clinical and immunomicrobiome correlates of a standardized Qingpao Chushi Jiedu Fang regimen in palmoplantar pustulosis.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Palmoplantar pustulosis (PPP) is a chronic inflammatory dermatosis with limited therapeutic options. Traditional Chinese Medicine (TCM) formulations may benefit PPP, yet microbiome-immune mechanisms underlying clinical response remain unclear. Objectives: To evaluate whether an 8-week standardized Qingpao Chushi Jiedu Fang (QCF) regimen is associated with coordinated changes in clinical severity, oral microbiota, and circulating cytokines in PPP. Methods: Thirty PPP patients received an 8-week standardized Qingpao Chushi Jiedu Fang (QCF) regimen. Clinical severity (PPPASI, Palmoplantar Pustulosis Area and Severity Index; Dermatology Life Quality Index, DLQI; pruritus/pain Visual Analogue Scale, VAS), oral microbiota (16S rDNA sequencing), and serum cytokines (IL-1β, IL-4, IFN- Results: PPPASI significantly decreased from week 2 onward ( Conclusion: QCF treatment was associated with significant clinical improvement accompanied by oral microbiota remodeling and modulation of inflammatory cytokines. These findings support a potential microbiome-immune axis in PPP and warrant further controlled studies. Clinical trial registration: http://www.itmctr.org, ITMCTR2025001530.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.